Healinature EyeWell Formula redzei un acīm ar cinku
Food supplement registered in Latvia
Register snapshot dated 2 May 2025. It does not establish the current status of the product.
- Number published by PVD
- 0000747/2016
- Type
- Food supplement
- Published status
- Status not provided in this export; the validity date is shown separately
- Licence holder
- Aptiekas produkcija, SIA
- Manufacturer
- Aptiekas produkcija, SIA
- Form
- Cietā želatīna kapsula
- Origin
- Latvija
- Register snapshot
- 2 May 2025
- Recommended daily intake (Latvian text)
- Pa 1 - 2 kapsulām dienā
- Published pack size
- Cietās želatīna kapsulas pa 550 mg
- Published packaging
- 32 kapsulas
This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.
The foreign register category does not determine the regulatory category of the product in France.
Published composition
| Published name | Published text and quantity | Recognised ingredient | Role or context |
|---|---|---|---|
| A VITAMĪNS | vitamins ; A VITAMĪNS ; 900 ; μg RE | Vitamine A | Vitamin or mineral |
| FOLSKĀBE | vitamins ; FOLSKĀBE ; 300 ; μg | Folates (vitamine B9) | Vitamin or mineral |
| Cinks | minerals ; Cinks ; 15 ; mg | Zinc | Vitamin or mineral |
| Melleņu ekstrakts ar 25% antocianidīnu | plants ; Melleņu ekstrakts ar 25% antocianidīnu ; Vaccinium myrtillus ; 60 ; mg | vaccinium myrtillus | Plant |
| Zaļās tējas lapu ekstrakts, kas satur 95% polifenolus | plants ; Zaļās tējas lapu ekstrakts, kas satur 95% polifenolus ; Camellia sinensis ; 100 ; mg | camellia sinensis | Plant |
| Kliņģerīšu ekstrakts, kas satur 12mg luteīnu | plants ; Kliņģerīšu ekstrakts, kas satur 12mg luteīnu ; Calendula officinalis ; 120 ; mg | calendula officinalis | Plant |
| Divdaivu ginka lapu ekstrakts (24% flavonoīdi/6% ginkolīdi) | plants ; Divdaivu ginka lapu ekstrakts (24% flavonoīdi/6% ginkolīdi) ; Ginkgo biloba ; 70 ; mg | ginkgo biloba | Plant |
| Žibulīšu ziedu un lapu ekstrakts 4:1 | plants ; Žibulīšu ziedu un lapu ekstrakts 4:1 ; Euphrasia officinalis ; 400 ; mg | euphrasia officinalis | Plant |
| Cietā kapsula no želatīna | otherIngredients ; Cietā kapsula no želatīna | Not recognised | Role not identified |
| Bioflavonoīdu komplekss (no citrusu augļiem) | otherIngredients ; Bioflavonoīdu komplekss (no citrusu augļiem) ; 30 ; mg | Not recognised | Role not identified |
Quantities are reproduced as published. The export does not specify their basis: the recommended daily intake cannot be used to calculate a daily dose. No daily dose is estimated. Latvian names are retained without translation.
Manufacturer countries
Latvija
French and European references for recognised ingredients
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
annexe III, partie B (règlement (UE) 2022/2340). Regulation (EC) No 1925/2006, latest consolidated version, retrieved 21 October 2026, source updated 26 November 2025.
- Information
Amount read: 30 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 900 µg RE. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Ambiguous amount: no numerical value retained for comparison.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 300 µg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 200 µg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSAEuropean Food Safety Authority. reference for adults: 1,000 µg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
Amount read: 15 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 15 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSA reference for adults: 25 mg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
Amount read: 60 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
vaccinium myrtillus is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Amount read: 100 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
camellia sinensis is on the list of plants allowed in food supplements (Order of 24 June 2014). Restriction: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
annexe III, partie B (règlement (UE) 2022/2340). Regulation (EC) No 1925/2006, latest consolidated version, retrieved 21 October 2026, source updated 26 November 2025.
- Information
Amount read: 120 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
calendula officinalis is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Amount read: 70 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
ginkgo biloba is on the list of plants allowed in food supplements (Order of 24 June 2014). Restriction: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Amount read: 400 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
euphrasia officinalis is not on the plant list of the Order of 24 June 2014: this is not a prohibition (a product legally sold in another Union country may contain it).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
Unrecognised ingredients are not assessed. The absence of a signal does not establish product compliance.
Official source
Internet Archive copy dated 3 May 2025
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Melleņu ekstrakts ar 25% antocianidīnu
Read the warning, when it applies and the studies cited
BILBERRY - VACCINIUM MYRTILLUS - Buccal
Route of administration: Buccal (Blumenthal et al. 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 30 January 2026
BILBERRY - VACCINIUM MYRTILLUS - Oral
Route of administration: Oral (Blumenthal et al. 2000)
Cautions and warnings
Condition of application: Relief of diarrhea.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
- Kliņģerīšu ekstrakts, kas satur 12mg luteīnu
Read the warning, when it applies and the studies cited
CALENDULA - CALENDULA OFFICINALIS - Buccal
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2018).
Sources cited by Health Canada (1)
- EMA 2018: European Medicines Agency. European Union herbal monograph on Calendula officinalis L., flos. 2018. [Accessed 2024, October 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-calendula-officinalis-l-flos-revision-1_en.pdf.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days (EMA 2018).
Sources cited by Health Canada (1)
- EMA 2018: European Medicines Agency. European Union herbal monograph on Calendula officinalis L., flos. 2018. [Accessed 2024, October 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-calendula-officinalis-l-flos-revision-1_en.pdf.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Health Canada monograph dated 28 March 2025
CALENDULA - CALENDULA OFFICINALIS - Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Contraindications
Do not use if you are pregnant (Brinker 2010; Bradley 2006).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (UK): British Herbal Medicine Association; 2006.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Health Canada monograph dated 30 January 2026
CALENDULA - CALENDULA OFFICINALIS - Topical
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- Divdaivu ginka lapu ekstrakts (24% flavonoīdi/6% ginkolīdi)
Read the warning, when it applies and the studies cited
GINKGO - GINKGO BILOBA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).
Sources cited by Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
- WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
- OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Contraindications
Do not use if you are having a surgery (Gardner and McGuffin 2013).
Sources cited by Health Canada (1)
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).
Sources cited by Health Canada (3)
- Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Systematic review
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Healinature EyeWell Formula redzei un acīm ar cinku”, https://compoatlas.com/en/supplements/latvia/6040-healinature-eyewell-formula-redzei-un-acim-ar-cinku, updated 28 October 2026.